Medical Marijuana and the Opioid Crisis
Can marijuana be used as an adjunct to or substitute for opioids in the treatment of chronic pain
to potentially alleviate the opioid crisis?
CSL Behring Will Discontinue Carimune NF in Third Quarter 2018
Discontinuation of the product is due to the preference among healthcare professionals and patients for newer, more advanced immune globulin options.
VONVENDI Approved to Treat Von Willebrand Disease
The U.S. Food and Drug Administration has approved Shire’s VONVENDI, a recombinant von Willebrand factor treatment for perioperative management of bleeding in adults 18 years and older with von Willebrand disease.
FDA Approves First Biosimilar to Fight Cancer
The U.S. Food and Drug Administration approved Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), the first biosimilar drug to treat cancer.
First Treatment Approved by FDA to Treat EGPA
GlaxoSmithKline’s Nucala (mepolizumab) has been approved by the U.S. Food and Drug Administration to treateosinophilic granulomatosis with polyangiitis (EGPA).
New Pill May Kill the Flu Virus in Patients in 24 Hours
Japanese drug maker Shionogi has created an experimental compound delivered via a single-dose pill that has been shown to effectively kill the influenza (flu) virus in patients within a single day.
Mylan’s Ogivri Approved as Biosimilar to Herceptin
Mylan’s Ogivri (trastuzumab-dkst) has been approved by the U.S. Food and Drug Administration as a biosimilar to Genentech’s Herceptin (trastuzumab).
Subcutaneous Immune Globulin Effective as Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy
A Phase III, placebo-controlled study demonstrated both low-dose and high-dose therapy with a licensed, self-administered subcutaneous immune globulin product was efficacious and well-tolerated as maintenance treatment for patients with chronic inflammatory demyelinating polyneuropathy.
First Digital Pill for Mental Illness Approved by FDA
Abilify MyCite (aripiprazole tablets with sensor; Otsuka Pharmaceutical), the first digital ingestion tracking system, has been approved by the U.S. Food and Drug Administration.
FDA Issues Product Advisory for CSL Behring’s AlbuRx
CSL Behring noted the potential for fading print with more effect on the expiration dating on the patient tear-off portion of the vial label.
